| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3517 | Mtpdds | Novel mitochondria-targeted photoactivatable real-time probe, being phototriggered by either UV (one-photon) or NIR (two-photon) light to form a fluorescent coumarin product and facilitate the release of drug payload |
|
| DCC3518 | Mtsea Hydrobromide | Useful probe in the mapping of membrane proteins, such as ion channels and transports proteins, as well as enzymes and receptors. |
|
| DCC3519 | Mtsea Hydrochloride | Useful probe in the mapping of membrane proteins, such as ion channels and transports proteins, as well as enzymes and receptors. |
|
| DCC3520 | Multitarget Ligand B6 | Novel potent multitarget ligand |
|
| DCC3521 | Mura-in-1 (zinc6129841) | Novel potent MurA inhibitor |
|
| DCC3522 | Murizatoclax | Novel potent and selective MCL-1 inhibitor |
|
| DCC3523 | Mutant Idh1 Inhibitor | Novel potent mutant IDH1 R132H inhibitor |
|
| DCC3524 | Mv061194 | Novel potent and selective cathepsin K (Cat K) inhibitor |
|
| DCC3525 | Mw01-2-151srm | CNS-penetrant, selective restorer of injury- or disease-induced overproduction of proinflammatory cytokines towards homeostasis. Selective suppressor of beta amyloid (Aβ)-induced glia proinflammatory cytokine production |
|
| DCC3526 | mw1219 | Novel GPR119 agonist with Anti-Diabetic Efficacy in db/db Mice |
|
| DCC3527 | Mwp00839 | Novel mitophagy activator |
|
| DCC3528 | mycothiol | Major thiol in most actinomycetes involved in mycothiol biosynthesis and mycothiol-dependent enzymes such as mycothiol-dependent formaldehyde dehydrogenase and mycothione reductase |
|
| DCC3529 | Mycro1 | Novel inhibitor of the protein-protein interactions between the bHLHZip proteins c-Myc and Max |
|
| DCC3530 | Mycro2 | Novel inhibitor of the protein-protein interactions between the bHLHZip proteins c-Myc and Max |
|
| DCC3531 | My-d-4 | Novel inhibitor of zinc finger DHHC domain-containing (zDHHC) enzymes |
|
| DCC3532 | Myotoxin Ii (105-117) | Myotoxin II fragment |
|
| DCC3533 | myovin-1 | Novel potent, reversible and uncompetitive inhibitor of actin-stimulated ATPase activity of myosin V |
|
| DCC3534 | Myra-a | Novel inducer of apoptosis in a Myc-dependent manner, inhibiting Myc-driven transformation and disrupting MYC-Max interaction |
|
| DCC3535 | Myrtucommulone | Inhibitor of the chaperonin activity of HSP60, correlating to LONP and LRP130 aggregation |
|
| DCC3536 | Myxopyronin A | Bacterial RNA polymerase (RNAP) inhibitor |
|
| DCC3537 | Mzp-54 | Novel potent and selective PROTAC degrader of BRD3/4 |
|
| DCC3538 | N,n-dimethylsphingosine | Competitive inhibitor of both SPHK1 and SPHK2 |
|
| DCC3539 | n00236460 | Glucokinase activator (GKA) |
|
| DCC3540 | N6-allyladenosine | Novel RNA labeling probe through both metabolic and enzyme-assisted manners |
|
| DCC3541 | N6-methyl-d3-adenosine | Deuterium labeled m6A used in important m6A physiological pathways related studies |
|
| DCC3542 | Na-aaf | Alkylating agent, forming DNA adducts at the C-8 position in guanine, resulting in single strand breaks, demonstrating carcinogenic action |
|
| DCC3543 | Nabiximols | Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) combination for the treatment of multiple sclerosis (MS)-related moderate to severe spasticity |
|
| DCC3544 | N-acetylloline | Derivative of loline |
|
| DCC3545 | N-adamantanylglycinamide Hbr | Novel antiviral agent against the replication of influenza virus A/H3N2 subtype in Madin-Darby canine kidney (MDCK) cells |
|
| DCC3546 | Nadide | Coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage |
|
